Sagimet Biosciences (SGMT) to Release Earnings on Wednesday

Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Wednesday, May 21st. Analysts expect Sagimet Biosciences to post earnings of ($0.79) per share for the quarter.

Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.23. On average, analysts expect Sagimet Biosciences to post $-2 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Sagimet Biosciences Trading Up 6.5%

Sagimet Biosciences stock traded up $0.21 during mid-day trading on Monday, hitting $3.43. The company had a trading volume of 281,187 shares, compared to its average volume of 859,713. Sagimet Biosciences has a 12 month low of $1.73 and a 12 month high of $7.38. The company has a market capitalization of $105.22 million, a PE ratio of -1.95 and a beta of 2.32. The stock's 50 day moving average price is $3.06 and its two-hundred day moving average price is $4.13.

Institutional Trading of Sagimet Biosciences

An institutional investor recently bought a new position in Sagimet Biosciences stock. NewEdge Advisors LLC acquired a new stake in shares of Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 32,290 shares of the company's stock, valued at approximately $105,000. NewEdge Advisors LLC owned about 0.11% of Sagimet Biosciences at the end of the most recent reporting period. Institutional investors own 87.86% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a "buy" rating and issued a $32.00 price target on shares of Sagimet Biosciences in a research note on Tuesday, March 11th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $22.40.

About Sagimet Biosciences

Sagimet Biosciences Inc, a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis.